Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alecensa

Roche's Perjeta pertuzumab

European approval for Roche’s next-gen breast cancer drug

Perjeta now available in EU for use before surgery in early stage aggressive breast cancer

- PMLiVE

Roche pharma sales strong for first half of 2015

New and old cancer drugs boost revenue for the Swiss pharma firm

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

Roche Basel Switzerland

Roche planning ocrelizumab filings in early 2016

Firm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

EU flag

Europe wants scientific advice to become pluralistic

Commission endeavours to create a new science committee and reject a single advisor model

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links